- Conditions
- Healthy Adults
- Interventions
- KP-001, Metformin, Midazolam, Clarithromycin
- Drug
- Lead sponsor
- Kaken Pharmaceutical
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Glendale, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healty Volunteers
- Interventions
- KP-001, Rosuvastatin calcium10mg, Caffeine citrate, Fluvoxamine
- Drug
- Lead sponsor
- Kaken Pharmaceutical
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthy Adults, Hepatic Impairment
- Interventions
- KP-001
- Drug
- Lead sponsor
- Kaken Pharmaceutical
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Healthy Volunteers - Male and Female
- Interventions
- KP-001, Moxifloxacin 400 mg, Placebo
- Drug
- Lead sponsor
- Kaken Pharmaceutical
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Venous Malformations, Lymphatic Malformations, Klippel-Trenaunay Syndrome, CLOVES Syndrome
- Interventions
- KP-001, Placebo
- Drug
- Lead sponsor
- Kaken Pharmaceutical
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina